None

FDA approves oral inhibitor for ED

FDA approves avanafil and tafluprost

Santen’s Tapros Mini For Glaucoma And Ocular Hypertension Approved

Santen Pharmaceuticals received approval for their preservative-free ophthalmic solution Tapros Mini (tafluprost) for the treatment of glaucoma and ocular hypertension.

Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects.

PURPOSE: To compare the intraocular pressure (IOP) reduction over 24 h achieved with tafluprost (0.0015%) with that achieved with latanoprost (0.005%). METHODS: Twenty-seven healthy volunteers were st...

Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.

Objectives: The aim of this study was to evaluate the safety of preservative-free tafluprost in newly diagnosed patients and to confirm its efficacy in lowering intraocular pressure (IOP). Methods: Na...

Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects.

PURPOSE: To compare the drug efficacy of four prostaglandin analogues (PGAs) by bilateral treatment in normal subjects. METHODS: Three consecutive studies comparing latanoprost to three other PGAs (tr...

Tafluprost (Zioptan) - a new topical prostaglandin for glaucoma.

Erratum: Correction tafluprost (Zioptan) Medical Letter 2012; 54:31.